AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32472141 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet, Exercise, and Lifestyle interventions (IDEAL study)
Number of subjects: 920
Study 32472141 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEALPlus subset interventions (daily journals and body fat assessment)
Number of subjects: 920
Study 35068224 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injection (ABI)
Number of subjects: 90
Study 35068224 — intervention group
Group type: COMPARATOR
Intervention: Dry-needling alone
Number of subjects: 90
Study 33253933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 23 (FGF23)
Number of subjects: 0
Study 36151961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Foley's transcervical catheter and sublingual Misoprostol
Number of subjects: 0
Study 36151961 — intervention group
Group type: COMPARATOR
Intervention: Sublingual Misoprostol alone
Number of subjects: 0
Study 36269738 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based parenting program (e-learning program entitled 'Making a healthy deal with your child')
Number of subjects: 475
Study 36269738 — intervention group
Group type: COMPARATOR
Intervention: Control condition (existing school-based overweight prevention program without the e-learning component)
Number of subjects: 475
Study 36269738 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based parenting program
Number of subjects: 475
Study 34166231 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01
Number of subjects: 12
Study 36434080 — intervention group
Group type: EXPERIMENTAL
Intervention: Foliar Zn application
Number of subjects: 35
Study 36434080 — intervention group
Group type: EXPERIMENTAL
Intervention: Foliar Fe application
Number of subjects: 35
Study 36434080 — intervention group
Group type: EXPERIMENTAL
Intervention: Foliar Zn + Fe application
Number of subjects: 35
Study 36434080 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 33944897 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim 18F‐FDG‐PET after 2 cycles (I‐PET2)
Number of subjects: 1692
Study 33944897 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim 18F‐FDG‐PET after 4 cycles (I‐PET4)
Number of subjects: 1692
Study 33944897 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim 18F‐FDG‐PET after 3 cycles (I‐PET3)
Number of subjects: 1692
Study 33944897 — intervention group
Group type: COMPARATOR
Intervention: Interim 18F‐FDG‐PET after 1 cycle (I‐PET1)
Number of subjects: 1692
Study 32602362 — intervention group
Group type: EXPERIMENTAL
Intervention: Full version of the application 'Relieve my back' with evidence-based instructions and therapeutic exercises for LBP management
Number of subjects: 40
Study 32602362 — intervention group
Group type: COMPARATOR
Intervention: Placebo version of the application with instructions about nutrition
Number of subjects: 40
Study 35296289 — intervention group
Group type: EXPERIMENTAL
Intervention: Information related to AstraZeneca's vaccine safety
Number of subjects: 100
Study 35296289 — intervention group
Group type: EXPERIMENTAL
Intervention: Information related to misinformation
Number of subjects: 100
Study 35296289 — intervention group
Group type: EXPERIMENTAL
Intervention: Information related to individual health risks
Number of subjects: 100
Study 35296289 — intervention group
Group type: EXPERIMENTAL
Intervention: Information related to public health risks
Number of subjects: 100
Study 35234092 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DR (bDRV 800 mg + dolutegravir 50 mg)
Number of subjects: 27
Study 35234092 — intervention group
Group type: COMPARATOR
Intervention: 3DR (boosted darunavir + two NRTIs)
Number of subjects: 27
Study 33021688 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-focus magnification with second-generation narrow-band imaging (NF-NBI)
Number of subjects: 4523
Study 33021688 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 4523
Study 33021688 — intervention group
Group type: COMPARATOR
Intervention: Second-generation narrow-band imaging (2G-NBI)
Number of subjects: 4523
Study 616765640 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee task
Number of subjects: 18
Study 616765640 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder task
Number of subjects: 18
Study 616765640 — intervention group
Group type: COMPARATOR
Intervention: Transfer task (after swapping models)
Number of subjects: 18
Study 34554225 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban forest intervention program
Number of subjects: 76
Study 34554225 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 34554225 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating
Number of subjects: 76
Study 33031298 — intervention group
Group type: EXPERIMENTAL
Intervention: SUZY forceps
Number of subjects: 60
Study 33031298 — intervention group
Group type: COMPARATOR
Intervention: Magill forceps
Number of subjects: 60
Study 33166580 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid and cyclophosphamide
Number of subjects: 86
Study 33166580 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus and rituximab
Number of subjects: 86
Study 33399273 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMNCs
Number of subjects: 50
Study 33399273 — intervention group
Group type: COMPARATOR
Intervention: PCCs
Number of subjects: 50
Study 32452344 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg once daily
Number of subjects: 290
Study 32452344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 36267016 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended behavioral intervention (JASPER + EMT)
Number of subjects: 31
Study 33998020 — intervention group
Group type: EXPERIMENTAL
Intervention: fGSH (face-to-face guided self-help)
Number of subjects: 180
Study 33998020 — intervention group
Group type: EXPERIMENTAL
Intervention: eGSH (email guided self-help)
Number of subjects: 180
Study 33998020 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (control)
Number of subjects: 180
Study 32299093 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of MDS‐associated phenotypic alterations (MDS‐PA) at diagnosis
Number of subjects: 285
Study 32299093 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS‐PA
Number of subjects: 285
Study 32299093 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS‐PA at diagnosis
Number of subjects: 285
Study 32299093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamics of MDS‐PA after autologous transplant
Number of subjects: 285
Study 32299093 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS‐associated mutations after high-dose therapy
Number of subjects: 285
Study 34674069 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD‐10 codes for cirrhosis
Number of subjects: 1317
Study 34674069 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD‐10 codes for portal hypertensive complications
Number of subjects: 1317
Study 33091934 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectal malformation (ARM) patients
Number of subjects: 817
Study 33091934 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and gender-matched individuals)
Number of subjects: 817
Study 32801257 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose (SPD) 2 L polyethylene glycol electrolyte solution, 1 L PEG between 8-9 pm the day before and 1 L PEG between 5-6 am on the day of colonoscopy.
Number of subjects: 295
Study 32801257 — intervention group
Group type: COMPARATOR
Intervention: Single-dose (SID) 2 L polyethylene glycol electrolyte solution, 2 L PEG between 4-6 am on the day of colonoscopy.
Number of subjects: 295
Study 32801257 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose (SPD) group
Number of subjects: 295
Study 32801257 — intervention group
Group type: COMPARATOR
Intervention: Single-dose (SID) group
Number of subjects: 295
Study 36061557 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous access endovascular repair
Number of subjects: 0
Study 36061557 — intervention group
Group type: COMPARATOR
Intervention: Cutdown access endovascular repair
Number of subjects: 0
Study 34481095 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Hz tACS for 26.67 min daily for three days (Long Exposure Theta group)
Number of subjects: 3
Study 34481095 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Hz tACS for 5.33 min daily (Short Exposure Theta group)
Number of subjects: 3
Study 34481095 — intervention group
Group type: COMPARATOR
Intervention: 1-Hz tACS for 26.67 min (Control group)
Number of subjects: 3
Study 35834196 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge-focused program (targeted toward high autonomous motivation)
Number of subjects: 68
Study 35834196 — intervention group
Group type: COMPARATOR
Intervention: Rewards-focused program (targeted toward low autonomous motivation)
Number of subjects: 68
Study 32319870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Filtering Efficiency (CFE) measured through ERP correlates during a delayed-match-to-sample task.
Number of subjects: 0
Study 32319870 — intervention group
Group type: COMPARATOR
Intervention: Low-Cognitive Filtering Efficiency (Low-CFE) individuals
Number of subjects: 0
Study 35235653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside reverse transcriptase inhibitor + integrase strand transfer inhibitor ART
Number of subjects: 4907
Study 35235653 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 4907
Study 32711578 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 186
Study 32711578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 186
Study 32711578 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 186
Study 35043578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow-derived cells (BMCs)
Number of subjects: 85
Study 35043578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 33685825 — intervention group
Group type: EXPERIMENTAL
Intervention: SUP with omeprazole
Number of subjects: 144
Study 33685825 — intervention group
Group type: COMPARATOR
Intervention: No SUP (Control)
Number of subjects: 144
Study 33685825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 144
Study 35084948 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus endocrine therapy (ET)
Number of subjects: 5807
Study 35084948 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus ET
Number of subjects: 5807
Study 35084948 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone
Number of subjects: 5807
Study 32797376 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) followed by chemoradiotherapy (CRT) - TPF arm
Number of subjects: 439
Study 32797376 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) followed by chemoradiotherapy (CRT) - PF arm
Number of subjects: 439
Study 32797376 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) alone
Number of subjects: 439
Study 32797376 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) followed by chemoradiotherapy (CRT) - TPF or PF arm
Number of subjects: 439
Study 35577745 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 71
Study 35577745 — intervention group
Group type: COMPARATOR
Intervention: Mucosamin
Number of subjects: 71
Study 35577745 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 71
Study 34398667 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg base/kg of body weight) plus primaquine (0.5 mg base/kg/day for 14 days)
Number of subjects: 641
Study 34398667 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg base/kg of body weight) plus primaquine (1 mg/kg/day for 7 days)
Number of subjects: 641
Study 34398667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (dihydroartemisinin at 7 mg/kg and piperaquine at 55 mg/kg) plus primaquine (0.5 mg base/kg/day for 14 days)
Number of subjects: 641
Study 34398667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (dihydroartemisinin at 7 mg/kg and piperaquine at 55 mg/kg) plus primaquine (1 mg/kg/day for 7 days)
Number of subjects: 641
Study 32934335 — intervention group
Group type: EXPERIMENTAL
Intervention: P11-4 following a single application of fluoride varnish (22,600 ppm)
Number of subjects: 108
Study 32934335 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (22,600 ppm) alone
Number of subjects: 108
Study 32934335 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 108
Study 34806426 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 15
Study 34806426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 32166899 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day Linagliptin
Number of subjects: 20
Study 32166899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34561393 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS over M1, dorsolateral prefrontal cortex, operculo-insular cortex
Number of subjects: 130
Study 34561393 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (active groups)
Number of subjects: 130
Study 34561393 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 130
Study 33166256 — intervention group
Group type: EXPERIMENTAL
Intervention: Merged model combining radiomic features and deep learning scores
Number of subjects: 217
Study 33166256 — intervention group
Group type: EXPERIMENTAL
Intervention: Merged model
Number of subjects: 217
Study 33509107 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (Actilyse® 1 mg/ml)
Number of subjects: 18
Study 33509107 — intervention group
Group type: COMPARATOR
Intervention: Citrate (Citra-LockTM 4%)
Number of subjects: 18
Study 33509107 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 18
Study 33509107 — intervention group
Group type: COMPARATOR
Intervention: Citrate
Number of subjects: 18
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: Drusen thickness at the fovea for eyes progressing to MNV
Number of subjects: 518
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: Drusen thickness at the fovea for eyes progressing to MA
Number of subjects: 518
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: Drusen thickness at the fovea for eyes without disease progression
Number of subjects: 518
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: Drusen thickness at 0.5-mm eccentricity for eyes progressing to MNV
Number of subjects: 518
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: Drusen thickness at 0.5-mm eccentricity for eyes progressing to MA
Number of subjects: 518
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: Drusen thickness at 0.5-mm eccentricity for eyes without disease progression
Number of subjects: 518
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: HRF thickness at the foveal center for eyes progressing to MNV
Number of subjects: 518
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: HRF thickness at the foveal center for eyes progressing to MA
Number of subjects: 518
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: HRF thickness at the foveal center for eyes without disease progression
Number of subjects: 518
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: HRF thickness at 0.5-mm eccentricity for eyes progressing to MA
Number of subjects: 518
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: HRF thickness at 0.5-mm eccentricity for eyes progressing to MNV
Number of subjects: 518
Study 32379287 — intervention group
Group type: EXPERIMENTAL
Intervention: HRF thickness at 0.5-mm eccentricity for eyes without disease progression
Number of subjects: 518
Study 35654408 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser resection
Number of subjects: 80
Study 35654408 — intervention group
Group type: COMPARATOR
Intervention: High-frequency electrocautery
Number of subjects: 80
Study 34161981 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifactor structure of the Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 0
Study 34161981 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis of HADS
Number of subjects: 0
Study 32306033 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitter promotion of articles
Number of subjects: 696
Study 32306033 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no active tweeting)
Number of subjects: 696
Study 35909375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 100
Study 35909375 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite-coated uncemented hemiarthroplasty
Number of subjects: 100
Study 34407667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemia control
Number of subjects: 0
Study 34407667 — intervention group
Group type: COMPARATOR
Intervention: Overall A effect
Number of subjects: 0
Study 34407667 — intervention group
Group type: COMPARATOR
Intervention: Simple A effect
Number of subjects: 0
Study 34969311 — intervention group
Group type: EXPERIMENTAL
Intervention: Video format educational material
Number of subjects: 71
Study 34969311 — intervention group
Group type: COMPARATOR
Intervention: Paper handout educational material
Number of subjects: 71
Study 32891191 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS6 with aluminium phosphate (AlPO4) 5 μg
Number of subjects: 364
Study 32891191 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS6 without AlPO4 5 μg
Number of subjects: 364
Study 32891191 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS6 with aluminium phosphate (AlPO4) 10 μg
Number of subjects: 364
Study 32891191 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS6 without AlPO4 10 μg
Number of subjects: 364
Study 32891191 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS6 with aluminium phosphate (AlPO4) 20 μg
Number of subjects: 364
Study 32891191 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS6 without AlPO4 20 μg
Number of subjects: 364
Study 32891191 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline control)
Number of subjects: 364
Study 32891191 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS6 (all groups)
Number of subjects: 364
Study 32891191 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS6 (various doses)
Number of subjects: 364
Study 32711565 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod (2 vials of 400 mg daily) with betamethasone 0.5-1 mg on need
Number of subjects: 22
Study 32711565 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 0.5-1 mg on need
Number of subjects: 22
Study 35340120 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA) 325 mg every 12 hours plus f‐TCC (fluocinolone‐based triple combination cream) every 24 hours
Number of subjects: 44
Study 35340120 — intervention group
Group type: COMPARATOR
Intervention: Oral tranexamic acid (TA) 325 mg every 12 hours
Number of subjects: 44
Study 33980514 — intervention group
Group type: EXPERIMENTAL
Intervention: Crescer em Grande! (CeG!) intervention
Number of subjects: 216
Study 32243384 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with conventional drug treatment
Number of subjects: 120
Study 32243384 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatment
Number of subjects: 120
Study 36429477 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based physical exercise program (50 min sessions, 3 times a week for 5 weeks)
Number of subjects: 40
Study 36429477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 35672830 — intervention group
Group type: EXPERIMENTAL
Intervention: RETURN intervention delivered by dental nurses, involving booklets and video clips, supportive conversations, personal goal setting, and follow-up texts.
Number of subjects: 1180
Study 33103504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung sonography
Number of subjects: 88
Study 33103504 — intervention group
Group type: COMPARATOR
Intervention: Auscultation
Number of subjects: 88
Study 35130200 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive opioid education session
Number of subjects: 120
Study 35130200 — intervention group
Group type: COMPARATOR
Intervention: Usual care education
Number of subjects: 120
Study 34351608 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg daily
Number of subjects: 165
Study 34351608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 34353696 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 baseline levels in hospitalized COVID-19 patients
Number of subjects: 100
Study 34353696 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels in severe COVID-19 patients
Number of subjects: 100
Study 34353696 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 plasma levels
Number of subjects: 100
Study 34353696 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IL-6 elevation and high serum glucose levels
Number of subjects: 100
Study 34353696 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in IL6 and IL6R gene region
Number of subjects: 100
Study 34353696 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-6 levels above 150 pg/ml
Number of subjects: 100
Study 37735383 — intervention group
Group type: EXPERIMENTAL
Intervention: Same day discharge (G1)
Number of subjects: 72
Study 37735383 — intervention group
Group type: COMPARATOR
Intervention: First day after discharge (G2)
Number of subjects: 72
Study 37735383 — intervention group
Group type: COMPARATOR
Intervention: Second day after discharge (G3)
Number of subjects: 72
Study 37735383 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction scores
Number of subjects: 72
Study 37735383 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with unsuccessful same-day discharge
Number of subjects: 72
Study 33546677 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound imaging (RUSI) as visual biofeedback during trunk muscle contraction.
Number of subjects: 40
Study 33546677 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visual feedback).
Number of subjects: 40
Study 36071520 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate‐mefloquine (AS/MQ)
Number of subjects: 211